Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for TransMedics Group's Debt-to-EBITDA or its related term are showing as below:
TMDX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -66.98 Med: -1.22 Max: 7.41
Current: 6.18
During the past 10 years, the highest Debt-to-EBITDA Ratio of TransMedics Group was 7.41. The lowest was -66.98. And the median was -1.22.
TMDX's Debt-to-EBITDA is ranked worse than 87.21% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs TMDX: 6.18
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
TransMedics Group Debt-to-EBITDA Related Terms
TransMedics Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for TransMedics Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMDX vs ESTA, AXGN, NVCR: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, TransMedics Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransMedics Group Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TransMedics Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
TransMedics Group (TMDX) has a Debt-to-EBITDA of 7.84 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on TransMedics Group. According to the industry distribution chart, TransMedics Group ranks #409 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 87.2%.
Is TransMedics Group's Debt-to-EBITDA too high?
TransMedics Group's current Debt-to-EBITDA is 7.84. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. TransMedics Group's value of 7.84 is 390% above this industry median. Based on the distribution chart, TransMedics Group ranks #409 out of 469 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TransMedics Group has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's Debt-to-EBITDA compare to ESTA and AXGN?
According to the Medical Devices & Instruments industry distribution chart, TransMedics Group ranks #409 out of 469 companies for Debt-to-EBITDA. This places TransMedics Group in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. TransMedics Group's value of 7.84 is 390% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransMedics Group's current Debt-to-EBITDA of 7.84 is 390% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on TransMedics Group. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransMedics Group's current Debt-to-EBITDA is 7.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
Based on GuruFocus' analysis, TransMedics Group (TMDX) is currently considered Possible Value Trap. The stock's GF Value™ is $171.43, compared to a current price of $76.51 — trading 55.4% below its estimated fair value. The current Debt-to-EBITDA is 7.84 and 390% above the Medical Devices & Instruments industry median of 1.60. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For TransMedics Group (TMDX), the current Debt-to-EBITDA is 7.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TransMedics Group (TMDX) Overvalued in 2026?
Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued.
The current stock price of $76.51 is trading 55.4% below its estimated GF Value™ of $171.43.
GuruFocus considers TransMedics Group to be Possible Value Trap.
Key valuation signals for TMDX:
Debt-to-EBITDA: 7.84
GF Value™: $171.43 vs. price of $76.51 (55.4% below fair value)
Industry Position: 390% above the Medical Devices & Instruments median (#409 of 469)
No single metric tells the full story. See the TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score
Get the complete analysis for TMDX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMDX has been successfully added to your 
